FACT SHEET: Financial Communications
From initial public offerings to quarterly earnings, MCS provides accurate, reliable financial communications services. We help clients make major material announcements, increase awareness among investors and develop relationships with key business media. Overall, these activities attempt to ensure consistency of messaging among financial and medical communities, enhance the company's image of financial strength and long-term viability, and demonstrate responsiveness to investors.
Reaching Out to the Financial Community
Through targeted media campaigns, national and regional speaking engagements and interviews with top financial media, MCS helps its clients reach analysts, financial journalists and key investors.
- In late 2005, MCS helped biomedical developer Recom Managed Systems (now Signalife) announce its new listing on the American Stock Exchange. The CEO and actor Joe Pesci, a stockholder in the company, rang the AMEX opening bell and took part in a number of radio and television interviews to announce the milestone and showcase the company's technology.
- To support Synergetics USA's ongoing communication with investors, MCS works closely with the CEO and the CFO to coordinate conference calls with investors to discuss quarterly earnings. In addition to serving as liaison for these calls, MCS reaches out to select business and financial media to ensure coverage of the quarter's financial performance.
Going Public
When biotechnology company Ribapharm was spun off from ICN Pharmaceuticals through an initial public offering of 26 million shares, MCS' targeted media relations raised awareness of the company among key audiences and secured interviews with top financial reporters for the company's CEO from the floor of the New York Stock Exchange. Ribapharm messages reached an estimated audience of 74 million potential investors through media outlets including
Bloomberg,
Dow Jones,
Reuters,
CNBC,
CNNfn,
Marketwatch and
TheStreet.com.
Unifying Messages
When Novartis wanted to provide investors, analysts and financial reporters an eye-catching document outlining sales figures for its core businesses, MCS worked with the investor relations department to design and develop fact sheets that were shared among the business units for distribution to local financial media contacts. In a separate campaign, the corporation's investor relations department circulated the fact sheets to national business and financial reporters at top newspapers and financial publications, and featured them in investor kits distributed to analysts, brokerage houses and reporters, standardizing the reporting of sales figures for all core businesses.
Bringing U.S. Attention to an Emerging Company
For Swiss biotech firm Actelion, the U.S. was a new market where awareness of the company was low. Because its first drug approval would come from the U.S. Food and Drug Administration, MCS worked to raise the company's profile in the U.S. Before the meeting of the FDA's Cardiovascular and Renal Advisory Committee to review the product, MCS arranged for a road show featuring the CEO and the president of Actelion, securing an interview on Bloomberg Television the morning of the meeting and additional coverage following the decision of the committee. MCS also provided strategic counsel in preparation for analyst calls, ensuring that positive messages about the company would reach investors.
